These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27574988)

  • 1. Medicinal Product Regulation: Portugal׳s Framework.
    Herdeiro MT; Bastos PD; Teixeira-Rodrigues A; Roque F
    Clin Ther; 2016 Sep; 38(9):2118-2126.e2. PubMed ID: 27574988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic aspects of the new Spanish laws on pharmaceutical preparations.
    Antoñanzas F; Oliva J; Pinillos M; Juàrez C
    Eur J Health Econ; 2007 Sep; 8(3):297-300. PubMed ID: 17401592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States.
    Qu L; Zou W; Wang Y; Wang M
    Phytomedicine; 2018 Mar; 42():219-225. PubMed ID: 29655689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
    Dejas-Eckertz P; Schäffner G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Regulation about generics approval].
    Laguna-Goya N; Blázquez-Pérez A; Pozo-Hernández C
    Farm Hosp; 2006; 30(6):379-84. PubMed ID: 17298196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH
    Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of Medicines in Portugal: A Retrospective Review of Medicine Recalls (2000-2015).
    Machado Reis AT; Berardo BFR; Loureiro R
    PDA J Pharm Sci Technol; 2018; 72(1):44-49. PubMed ID: 29030530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.
    Borg JJ; Robert JL; Wade G; Aislaitner G; Pirozynski M; Abadie E; Salmonson T; Vella Bonanno P
    J Pharm Pharm Sci; 2009; 12(2):181-98. PubMed ID: 19732496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
    Martinac AI; Tomić S; Simicić M
    Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Causes of drug shortages in the legal pharmaceutical framework.
    De Weerdt E; Simoens S; Hombroeckx L; Casteels M; Huys I
    Regul Toxicol Pharmacol; 2015 Mar; 71(2):251-8. PubMed ID: 25591547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Main Reasons for Registration Application Refusal of Generic and Similar Pharmaceutical Drug Products by the Brazilian Health Regulatory Agency (ANVISA).
    do Carmo AC; Piras SS; Rocha NF; Gratieri T
    Biomed Res Int; 2017; 2017():7894937. PubMed ID: 28280742
    [No Abstract]   [Full Text] [Related]  

  • 19. [EU law on marketing authorization of medicines. History, current state of development and perspectives].
    Nettesheim M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):705-12. PubMed ID: 18560781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
    Enzmann H; Broich K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.